ERBB2 and neoplasm: The largest difference was noted for invasive ER-positive/HER2-negative tumours (10 recurrences with anastrozole vs 28 with tamoxifen; HR 0·37 [95% CI 0·18–0·75], p=0·0060; figure 3).